X-Linked Adrenoleukodystrophy: Clinical Trials

2 trials for X-Linked Adrenoleukodystrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Withdrawn 1
Phase 11Withdrawn 1

Follow X-Linked Adrenoleukodystrophy: new trials by email Literature Review of X-Linked Adrenoleukodystrophy trials Research Report on X-Linked Adrenoleukodystrophy

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy
Sobetirome (NV1205) - X-Linked Adrenoleukodystrophy
Phase 1 / Phase 2WithdrawnNeuroVia, Inc.2018-08-012019-03-07
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy
Pioglitazone - Adrenomyeloneuropathy, X-linked Adrenoleukodystrophy
Phase 2CompletedPujol, Aurora, M.D.182016-01-012019-09-10

Narrower conditions

Adrenoleukodystrophy (2)

Broader conditions

Adrenal Gland Diseases (2)  ·  Adrenal Insufficiency (2)  ·  Brain Diseases (2)  ·  Brain Diseases, Metabolic (2)  ·  Brain Diseases, Metabolic, Inborn (2)  ·  Central Nervous System Diseases (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Demyelinating Diseases (2)  ·  Endocrine System Diseases (2)  ·  Genetic Diseases, Inborn (2)  ·  Genetic Diseases, X-Linked (2)  ·  Hereditary Central Nervous System Demyelinating Diseases (2)  ·  Heredodegenerative Disorders, Nervous System (2)  ·  Intellectual Disability (2)  ·  Leukoencephalopathies (2)

Interventions

GC 1 compound (1)  ·  Pioglitazone (1)

Sponsors

NeuroVia, Inc. (1)  ·  Pujol, Aurora, M.D. (1)

Countries

Argentina (1)  ·  Australia (1)  ·  Chile (1)  ·  Colombia (1)  ·  France (1)  ·  Russia (1)  ·  Spain (1)  ·  Ukraine (1)  ·  United Kingdom (1)

Top investigators

John Henderson, MD (1)